Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1044 in Subjects With Malignant Solid Tumors

NCT04424641 is registered in ClinicalTrials.gov with Genmab as lead sponsor.

NCT NCT04424641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04424641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1044 in Subjects With Malignant Solid Tumors
Lead sponsor
Genmab
Phase
Phase 1/2
Overall status
Terminated
Start date
July 15, 2020
Completion date
October 29, 2021
Enrollment
48 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, esophageal cancer, locally advanced or metastatic solid tumor(s), non-small cell lung cancer (nsclc), prostate cancer, squamous cell carcinoma of head and neck (scchn), triple negative breast cancer (tnbc), uterine cancer